Pfizer Inc ((PFE)), Astellas Pharma ((ALPMF)), Astellas Pharma ((ALPMY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. and Astellas Pharma Inc. are conducting a significant clinical study titled ‘TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER.’ The study aims to evaluate the safety and efficacy of combining talazoparib with enzalutamide compared to a placebo with enzalutamide in treating men with DDR-deficient metastatic castration-sensitive prostate cancer (mCSPC). This research could have substantial implications for prostate cancer treatment.
The intervention being tested involves the drug combination of talazoparib and enzalutamide. Talazoparib is a PARP inhibitor, and enzalutamide is an androgen receptor inhibitor. This combination is intended to enhance treatment effectiveness in patients with specific genetic mutations associated with prostate cancer.
The study follows a randomized, double-blind, parallel assignment model, ensuring unbiased results. Participants are randomly assigned to either the experimental group receiving talazoparib with enzalutamide or the control group receiving a placebo with enzalutamide. The primary purpose of this study is treatment-focused, with quadruple masking to maintain objectivity.
The study began on May 12, 2021, and is currently active but not recruiting new participants. The last update was submitted on August 11, 2025. These dates are crucial for tracking the study’s progress and anticipating when results might be available.
This study’s outcome could significantly impact Pfizer and Astellas Pharma’s stock performance and investor sentiment. Success in demonstrating the efficacy of this drug combination could position these companies favorably in the competitive oncology market, potentially influencing their market share and investor confidence.
The study is ongoing, with further details available on the ClinicalTrials portal.